GLYCANID Trademark

Trademark Overview


On Tuesday, November 16, 2021, a trademark application was filed for GLYCANID with the United States Patent and Trademark Office. The USPTO has given the GLYCANID trademark a serial number of 97128272. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Friday, March 24, 2023. This trademark is owned by Glyde Bio, Inc.. The GLYCANID trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in immunotherapy; chemical preparations for medical and pharmaceutical purposes; diagnostic preparations for medical purposes; vaccines

Pharmaceutical research and development; biotechnology research and development; research and development in the field of immunotherapy for the treatment of cancer; development of pharmaceutical preparations and therapeutics and vaccines; chemical and biological engineering of biological molecules; providing research and development in the field of new drugs, pharmaceuticals, therapeutics, diagnostic reagents, and methods for diagnosing, prognosing, monitoring and therapy thereof
glycanid

General Information


Serial Number97128272
Word MarkGLYCANID
Filing DateTuesday, November 16, 2021
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateFriday, March 24, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in immunotherapy; chemical preparations for medical and pharmaceutical purposes; diagnostic preparations for medical purposes; vaccines
Goods and ServicesPharmaceutical research and development; biotechnology research and development; research and development in the field of immunotherapy for the treatment of cancer; development of pharmaceutical preparations and therapeutics and vaccines; chemical and biological engineering of biological molecules; providing research and development in the field of new drugs, pharmaceuticals, therapeutics, diagnostic reagents, and methods for diagnosing, prognosing, monitoring and therapy thereof

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, November 22, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, November 22, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGlyde Bio, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139

Trademark Events


Event DateEvent Description
Friday, March 24, 2023ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Friday, March 24, 2023ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Friday, March 24, 2023ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, September 6, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, September 6, 2022NON-FINAL ACTION E-MAILED
Tuesday, September 6, 2022NON-FINAL ACTION WRITTEN
Friday, August 26, 2022ASSIGNED TO EXAMINER
Monday, November 22, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, November 19, 2021NEW APPLICATION ENTERED